Swiss National Bank Apellis Pharmaceuticals, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Swiss National Bank holds 154,100 shares of APLS stock, worth $4.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

154,100

Previous 154,700 0.39%

Holding current value

$4.54 Million

Previous $5.93 Million 25.11%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$28.84 - $41.15 $17,304 - $24,690	-600 Reduced 0.39%	154,100 $4.44 Million
Q2 2024 Aug 08, 2024	BUY	$38.07 - $59.71 $548,208 - $859,824	14,400 Added 10.26%	154,700 $5.93 Million
Q1 2024 May 07, 2024	SELL	$55.39 - $72.47 $1.22 Million - $1.6 Million	-22,100 Reduced 13.61%	140,300 $8.25 Million
Q4 2023 Feb 06, 2024	SELL	$37.14 - $64.82 $623,952 - $1.09 Million	-16,800 Reduced 9.38%	162,400 $9.72 Million
Q3 2023 Nov 08, 2023	BUY	$23.65 - $89.22 $82,775 - $312,270	3,500 Added 1.99%	179,200 $6.82 Million
Q2 2023 Aug 09, 2023	SELL	$76.68 - $93.31 $1.17 Million - $1.43 Million	-15,300 Reduced 8.01%	175,700 $16 Million
Q1 2023 May 10, 2023	SELL	$46.59 - $66.96 $987,708 - $1.42 Million	-21,200 Reduced 9.99%	191,000 $12.6 Million
Q4 2022 Feb 08, 2023	BUY	$43.24 - $61.04 $436,724 - $616,504	10,100 Added 5.0%	212,200 $11 Million
Q3 2022 Nov 09, 2022	BUY	$44.76 - $69.66 $801,204 - $1.25 Million	17,900 Added 9.72%	202,100 $13.8 Million
Q2 2022 Aug 09, 2022	BUY	$35.07 - $59.21 $108,717 - $183,551	3,100 Added 1.71%	184,200 $8.33 Million
Q1 2022 May 09, 2022	BUY	$35.46 - $54.12 $432,612 - $660,264	12,200 Added 7.22%	181,100 $9.2 Million
Q4 2021 Feb 08, 2022	BUY	$30.74 - $49.16 $1.09 Million - $1.75 Million	35,500 Added 26.61%	168,900 $7.99 Million
Q3 2021 Nov 08, 2021	BUY	$31.4 - $69.84 $15,700 - $34,920	500 Added 0.38%	133,400 $4.4 Million
Q2 2021 Aug 06, 2021	BUY	$40.9 - $64.9 $126,790 - $201,190	3,100 Added 2.39%	132,900 $8.4 Million
Q1 2021 May 07, 2021	BUY	$40.8 - $57.39 $65,279 - $91,824	1,600 Added 1.25%	129,800 $5.57 Million
Q4 2020 Feb 05, 2021	SELL	$30.79 - $57.2 $267,873 - $497,640	-8,700 Reduced 6.36%	128,200 $7.33 Million
Q3 2020 Nov 09, 2020	BUY	$25.89 - $33.65 $59,547 - $77,395	2,300 Added 1.71%	136,900 $4.13 Million
Q2 2020 Aug 05, 2020	BUY	$24.8 - $38.49 $513,360 - $796,743	20,700 Added 18.17%	134,600 $4.4 Million
Q1 2020 May 08, 2020	BUY	$17.91 - $44.33 $512,226 - $1.27 Million	28,600 Added 33.53%	113,900 $3.05 Million
Q4 2019 Feb 06, 2020	BUY	$22.1 - $30.8 $48,620 - $67,760	2,200 Added 2.65%	85,300 $2.61 Million
Q3 2019 Nov 12, 2019	BUY	$24.09 - $32.18 $48,180 - $64,360	2,000 Added 2.47%	83,100 $2 Million
Q2 2019 Aug 02, 2019	BUY	$18.0 - $25.34 $30,600 - $43,078	1,700 Added 2.14%	81,100 $2.06 Million
Q1 2019 May 10, 2019	BUY	$12.81 - $19.82 $204,960 - $317,120	16,000 Added 25.24%	79,400 $1.55 Million
Q3 2018 Nov 08, 2018	BUY	$16.57 - $21.03 $565,037 - $717,123	34,100 Added 116.38%	63,400 $1.13 Million
Q2 2018 Aug 09, 2018	BUY	$19.63 - $30.0 $575,159 - $879,000	29,300 New	29,300 $645,000

Others Institutions Holding APLS

# of Institutions

306

Shares Held

112M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.24B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Apellis Pharmaceuticals, Inc. Transaction History